{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:48:54Z","timestamp":1792511334112,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007565","name":"Citrus Research and Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004419","name":"CRDF Global","doi-asserted-by":"publisher","award":["DAA3-A8-64084-01"],"award-info":[{"award-number":["DAA3-A8-64084-01"]}],"id":[{"id":"10.13039\/100004419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jvacx.2023.100354","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:48:06Z","timestamp":1689079686000},"page":"100354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of Chimeric Hepatitis B (HBV) \u2013 Norovirus (NoV) P particle as candidate vaccine against Hepatitis B and norovirus infection"],"prefix":"10.1016","volume":"14","author":[{"given":"Ernawati Arifin","family":"Giri-Rachman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marselina","family":"Irasonia Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-6823","authenticated-orcid":false,"given":"Ashwin","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putri Ayu","family":"Fajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annisa","family":"Nurul Ilmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie Sofie","family":"Retnoningrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-5830","authenticated-orcid":false,"given":"Rukman","family":"Hertadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apriliani","family":"Irawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys Emmanuella Putri","family":"Wojciechowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-5228","authenticated-orcid":false,"given":"Lijuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Suppl","key":"10.1016\/j.jvacx.2023.100354_b0005","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatol Baltim Md"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100354_b0010","first-page":"165","article-title":"Hepatitis B Vaccine and Immunoglobulin: Key Concepts","volume":"7","author":"Das","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jvacx.2023.100354_b0015","unstructured":"WHO. Hepatitis B [Internet]. 2022 [cited 2022 Oct 12]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.jvacx.2023.100354_b0020","doi-asserted-by":"crossref","unstructured":"Tseng TC, Huang LR. Immunopathogenesis of Hepatitis B Virus. J Infect Dis. 2017 Nov 16;216(suppl_8):S765\u2013S770.","DOI":"10.1093\/infdis\/jix356"},{"issue":"17","key":"10.1016\/j.jvacx.2023.100354_b0025","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection: A Review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jvacx.2023.100354_b0030","first-page":"420","article-title":"Hepatitis B virus and its sexually transmitted infection - an update","volume":"3","author":"Inoue","year":"2016","journal-title":"Microb Cell Graz Austria"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100354_b0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/genes10040260","article-title":"Meeting the Challenge of Eliminating Chronic Hepatitis B Infection","volume":"10","author":"Revill","year":"2019","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100354_b0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrgastro.2016.7","article-title":"Global strategies are required to cure and eliminate HBV infection","volume":"13","author":"Revill","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100354_b0045","first-page":"112","article-title":"Virus Infection: What Is Current and New","volume":"26","author":"Peters","year":"2019","journal-title":"Top Antivir Med"},{"issue":"12","key":"10.1016\/j.jvacx.2023.100354_b0050","doi-asserted-by":"crossref","first-page":"e1003784","DOI":"10.1371\/journal.ppat.1003784","article-title":"Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control?","volume":"9","author":"Bertoletti","year":"2013","journal-title":"PLOS Pathog"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100354_b0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.provac.2010.07.004","article-title":"Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies","volume":"2","author":"Guill\u00e9n","year":"2010","journal-title":"Procedia Vaccinol"},{"issue":"6","key":"10.1016\/j.jvacx.2023.100354_b0060","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/nnm.12.62","article-title":"Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus","volume":"7","author":"Tan","year":"2012","journal-title":"Nanomed"},{"issue":"50","key":"10.1016\/j.jvacx.2023.100354_b0065","first-page":"61","article-title":"Noroviruses: The Principal Cause of Foodborne Disease Worldwide","volume":"10","author":"Koo","year":"2010","journal-title":"Discov Med"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100354_b0070","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/JVI.01835-10","article-title":"Norovirus P particle, a novel platform for vaccine development and antibody production","volume":"85","author":"Tan","year":"2011","journal-title":"J Virol"},{"issue":"44","key":"10.1016\/j.jvacx.2023.100354_b0075","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1016\/j.vaccine.2011.07.139","article-title":"A candidate dual vaccine against influenza and noroviruses","volume":"29","author":"Xia","year":"2011","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.jvacx.2023.100354_b0080","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.1128\/JVI.01249-14","article-title":"Intranasal P Particle Vaccine Provided Partial Cross-Variant Protection against Human GII.4 Norovirus Diarrhea in Gnotobiotic Pigs. Perlman S, editor","volume":"88","author":"Kocher","year":"2014","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.jvacx.2023.100354_b0085","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1099\/vir.0.054080-0","article-title":"Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age","volume":"94","author":"Bui","year":"2013","journal-title":"J Gen Virol"},{"issue":"9","key":"10.1016\/j.jvacx.2023.100354_b0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/v12090955","article-title":"Evaluation of the 50% Infectious Dose of Human Norovirus Cin-2 in Gnotobiotic Pigs: A Comparison of Classical and Contemporary Methods for Endpoint Estimation","volume":"12","author":"Ramesh","year":"2020","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100354_b0095","doi-asserted-by":"crossref","first-page":"e63269","DOI":"10.1371\/journal.pone.0063269","article-title":"Norovirus P Particle Efficiently Elicits Innate, Humoral and Cellular Immunity","volume":"8","author":"Fang","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100354_b0100","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"issue":"15\u201316","key":"10.1016\/j.jvacx.2023.100354_b0105","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0264-410X(00)00364-9","article-title":"Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications","volume":"19","author":"Hilleman","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2023.100354_b0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.0818-9641.2004.01278.x","article-title":"Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen","volume":"82","author":"Aguilar","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100354_b0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2012.07.011","article-title":"Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus","volume":"96","author":"Akbar","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jvacx.2023.100354_b0120","unstructured":"Giri-Rachman E, Lusiany T, Poniman M, Sari I, Hertadi R, Retnoningrum D. Expression of Norovirus P Particle Chimeric-HBV Antigens as Intranasal Hepatitis B Prophylaxis and Therapeutic Vaccine Candidate. In: The IIER International Conference. New York; 2019. p. 72\u20136."},{"issue":"13","key":"10.1016\/j.jvacx.2023.100354_b0125","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3748\/wjg.v10.i13.1902","article-title":"Therapeutic polypeptides based on HBV core 18\u201327 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs","volume":"10","author":"Shi","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jvacx.2023.100354_b0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1023366013858","article-title":"HBcAg-Specific CD8 T Cells Play an Important Role in Virus Suppression, and Acute Flare-Up Is Associated with the Expansion of Activated Memory T Cells","volume":"23","author":"Shimada","year":"2003","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jvacx.2023.100354_b0135","unstructured":"The Chemical Department of the Faculty of Mathematics and Natural Sciences ITB. Percobaan 1 Protein: Reaksi Uji Terhadap Asam Amino Dan Penentuan Konsentrasi Protein [Internet]. 2017 [cited 2020 May 21]. Available from: http:\/\/biochem.chem.itb.ac.id\/wp-content\/uploads\/2015\/02\/Modul-1.pdf."},{"issue":"3","key":"10.1016\/j.jvacx.2023.100354_b0140","doi-asserted-by":"crossref","first-page":"e60374","DOI":"10.1371\/journal.pone.0060374","article-title":"Mycotoxin-Containing Diet Causes Oxidative Stress in the Mouse","volume":"8","author":"Hou","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jvacx.2023.100354_b0145","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.3390\/pharmaceutics11090472","article-title":"Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development","volume":"11","author":"Tan","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100354_b0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/rb\/rbu003","article-title":"Counting CD4+ and CD8+ T cells in the spleen: a novel in vivo method for assessing biomaterial immunotoxicity","volume":"1","author":"Shieh","year":"2014","journal-title":"Regen Biomater"},{"key":"10.1016\/j.jvacx.2023.100354_b0155","unstructured":"Janeway CA, Travers P, Walport M, Shlomchik MJ. B-cell activation by armed helper T cells. Immunobiol Immune Syst Health Dis 5th Ed [Internet]. 2001 [cited 2022 Nov 3]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK27142\/."},{"issue":"3\u20134","key":"10.1016\/j.jvacx.2023.100354_b0160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-2427(02)00046-6","article-title":"Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model","volume":"87","author":"Yuan","year":"2002","journal-title":"Vet Immunol Immunopathol"},{"issue":"26","key":"10.1016\/j.jvacx.2023.100354_b0165","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.vaccine.2008.03.085","article-title":"Virus-specific intestinal IFN-gamma producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs","volume":"26","author":"Yuan","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100354_b0170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbrc.2019.09.072","article-title":"Intranasal vaccination with HBs and HBc protein combined with carboxyl vinyl polymer induces strong neutralizing antibody, anti-HBs IgA, and IFNG response","volume":"520","author":"Sanada","year":"2019","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:29:24Z","timestamp":1792510164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136223000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":34,"alternative-id":["S2590136223000955"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100354","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Chimeric Hepatitis B (HBV) \u2013 Norovirus (NoV) P particle as candidate vaccine against Hepatitis B and norovirus infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100354"}}